CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH A once-hopeful antibody-drug conjugate for small-cell lung cancer (SCLC) failed to demonstrate a survival benefit in two large, randomized studies, and was found to be mostly toxic. The negative trial results have led to the end of a drug that was considered a promising potential antidote to deadly SCLC.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
